Swine feed premix operations classify Wujiapi Qi Powder Veterinary Grade API as a micro-ingredient whose handling is governed by segregation mechanics rather than by chemical stability alone. The powder is typically received with a bulk density between 0.38 g/mL and 0.62 g/mL and a sieve residue of ≤5% above 150 µm. If the difference between the API bulk density and the carrier bulk density exceeds 0.15 g/mL, the pre-blend will stratify during discharge, producing an assay drift of ±12–18% across 10 grab samples. To control this, the API is first diluted with lactose monohydrate or rice hull meal at 2–5 wt% of the final batch mass, passed through a 500 µm conical screen, and then loaded into a 1,000 L ribbon mixer at 80% working volume with an impeller speed of 15 rpm. The main mixing interval is 8–12 min; extending it beyond 15 min does not improve homogeneity and increases electrostatic carryover and dusting.

The relevant compliance framework for this route includes Regulation (EC) No 183/2005, Directive 2002/32/EC, GMP+ B1, and FAMI-QS. For residual solvent control in the dried extract, batch release should include limits under VICH GL18. The addition ratio is dose-derived: for a target dose of 20 mg/kg bodyweight and a daily feed intake of 4% bodyweight, the complete-feed level is 500 mg/kg, equivalent to 0.5 kg/t. A 10 kg/t premix intermediate therefore requires 50 g/kg API; the 25–100 g/kg range in the premix corresponds to final feed levels of 0.25–1.0 kg/t. Finished product types include medicated feed premix, top-dress powder, starter feed, and sow lactation feed. Carryover cleanup after each batch is verified by swab limits no greater than 1/1000 of the smallest batch API dose.

What Limits Reconstitution Clarity in Poultry Drinking-Water Granules?

The production constraint in poultry drinking-water granules is the balance between granule hardness and instant dissolution. In a 120 L fluid-bed granulator, Wujiapi Qi Powder Veterinary Grade API is loaded at 10–30 wt% of the dry granule mass with lactose monohydrate or sorbitol as filler and 3–5 wt% povidone K30 as binder. The spray rate is maintained below 120 g/min; when the spray rate exceeds this value at an inlet air temperature of 65°C, the granules form hard agglomerates and the reconstitution time increases from 4 min to more than 15 min in water at 25°C. The drying endpoint is controlled at a product temperature of 35–45°C and a loss-on-drying limit of ≤3.0%. The dried granule fraction is sieved between 200 µm and 850 µm; fines below 200 µm are recycled or removed because they create dust during sachet filling and can segregate in multi-dose packaging.

For drinking-water application, the granule active loading is selected so that a 10 g sachet containing 30 wt% API delivers 3 g active material, sufficient to prepare 100–200 L of stock solution at 15–30 mg/L. The final water concentration is derived from the prescribed dose and the flock’s water intake; at a daily water intake of 20% bodyweight, a target dose of 10 mg/kg corresponds to 50 mg/L. The solution is buffered to pH 5.5–6.5 because hard water above pH 8.5 slows hydration and increases haze. Compliance in this route is governed by EU Regulation 2019/6 for veterinary medicinal products, with dissolution checked under Ph. Eur. 2.9.3 and moisture determined by USP <921>. Terminal finished product types are water-soluble granules, oral powders, and concentrated stock solutions for proportioner dosing.

Injectable Solution Depyrogenation and Filter Compatibility Boundaries

Sterile compounding of Wujiapi Qi Powder Veterinary Grade API requires a defined control sequence because the extract is not a single-molecule drug substance. The dry API is first dissolved in Water for Injection at 25–35°C under high-shear mixing; the maximum solution load is held at 0.1–0.5% w/v, or 100–500 g per 100 L batch. Above 0.5% w/v, polysaccharide-rich fractions raise viscosity beyond 5 cP, and the 0.22 µm PVDF final filter capacity falls below 10 L/m². The solution is adjusted to pH 5.5–6.5 with citric acid or sodium citrate, and tonicity is set at 280–320 mOsm/kg using sodium chloride or mannitol. A 0.45 µm polypropylene prefilter is placed upstream of the final 0.22 µm membrane to remove aggregates and reduce premature blocking.

The sterile process boundary is that autoclaving at 121°C for 15 min is permitted only after the specific CoA lot passes a thermal-challenge test for color change and sub-visible particle increase. If the extract contains heat-sensitive polyphenols or reducing sugars, aseptic filtration in an ISO 14644-1 class 5 area is used instead. Compliance includes EU GMP Annex 1, Ph. Eur. 2.6.14 for bacterial endotoxins, Ph. Eur. 2.9.19 for particulate contamination, and USP <788> for injection particulate limits. Residual solvent release follows VICH GL18. Terminal finished product types are aqueous injectable solutions and sterile liquid parenterals for swine and cattle. Published filter-loading data for this specific botanical extract in Water for Injection are limited; a filter compatibility trial on each incoming lot is required before scale-up.

When the Extract Is Compressed into Companion Animal Tablets Without Prior Drying

When the powder is moved from warehouse to compression, the main failure mode is sticking and picking on punch faces, driven by hygroscopic uptake above 55% RH. The API is therefore pre-dried in a vacuum tray dryer at 40–50°C and ≤40% RH until the loss-on-drying value is ≤5.0%. The tablet formula uses 100–300 mg of Wujiapi Qi Powder Veterinary Grade API per unit, corresponding to 15–40 wt% of the core. Microcrystalline cellulose is included at 30–50 wt%, croscarmellose sodium at 2–5 wt% as disintegrant, colloidal silicon dioxide at 0.5–1.0 wt% as glidant, and magnesium stearate at 0.5–1.5 wt% as lubricant. The magnesium stearate level is kept below 1.5 wt% because higher levels delay disintegration beyond 15 min when the tablet hardness exceeds 120 N.

Compression is conducted on a rotary press with a 16-station turret at main compression force between 8 kN and 14 kN. Target hardness is 80–150 N, friability is controlled below 1.0% under USP <1216>, and disintegration time is verified under Ph. Eur. 2.9.1. Content uniformity follows USP <905>; residual solvent control follows VICH GL18; the finished veterinary medicinal product is placed under EU Regulation 2019/6. Terminal product types are chewable tablets, scored tablets, hard capsules filled with the same granulation, and larger oral boluses for companion animals. When wet granulation is required, the product temperature must not exceed 45°C because the botanical extract becomes tacky and non-dischargeable from high-shear granulators.

Ruminant oral drench production differs from dry premix handling because the API is introduced into a liquid vehicle where polysaccharide hydration controls both viscosity and dosing accuracy. In a 2,000 L stainless-steel compounding vessel, Wujiapi Qi Powder Veterinary Grade API is dispersed at 10–30 g/L under a high-shear mixer running at 3,000 rpm for 15 min. The vehicle contains propylene glycol at 5–15% v/v to suppress gelation, sodium benzoate at 0.1–0.2% w/v as preservative, and citric acid buffer to hold pH at 5.5–6.5. If the batch viscosity exceeds 100 mPa·s at 25°C, filling pumps show volumetric drift and neck-drip increases; the solution is then diluted or the mixing time is extended. After compounding, the liquid is passed through a 10 µm clarification filter and stored in closed stainless-steel tanks before filling.

The addition ratio is dose-derived. At a dosing volume of 0.5 mL/kg bodyweight, a 20 g/L solution delivers 10 mg/kg bodyweight. Compliance is governed by EU Regulation 2019/6, residual solvent limits under VICH GL18, and preservative efficacy testing under Ph. Eur. 5.1.3 for multi-dose containers. When well water is used for dilution at the farm, a 1:10 dilution sample should not exceed 10 NTU turbidity; higher turbidity indicates precipitation and requires softened water or a chelating agent before release. Terminal finished product types include oral drench, liquid feed supplement, and ruminal intubation solution.

Aquafeed Extrusion Thermal Input and Polysaccharide Retention

Pre-extrusion addition of polysaccharide powders to aquafeed lines creates a measurable recovery loss when the die temperature exceeds 85°C. In a twin-screw extruder with an L/D ratio of 25:1 and a die temperature of 105–125°C, direct addition of Wujiapi Qi Powder Veterinary Grade API before the preconditioner can reduce marker recovery by 20–35%, with the loss concentrated in the barrel zone where melt viscosity is highest. The preferred process is therefore post-extrusion vacuum coating: the API is dispersed in fish oil or vegetable oil at 0.5–2.0 wt% of pellet mass and sprayed onto pellets at 60–70°C under a vacuum of −0.08 MPa. This keeps the thermal exposure below 85°C and avoids the high-shear barrel section entirely.

The finished feed addition ratio is 1–5 kg/t, but the ratio is dose-derived and must be adjusted to the prescribed in-water or in-feed dose. For a daily feed intake of 2% bodyweight, a target dose of 10 mg/kg bodyweight corresponds to 500 mg/kg feed. Compliance for this route includes Regulation (EC) No 183/2005, Directive 2002/32/EC, GMP+ B1, and ISO 22000. Terminal finished product types are extruded sinking pellets, floating pellets, and top-dressed aquafeed. Because published retention data for this specific extract under extrusion temperatures are limited, each production line should undergo a mass-balance trial before commercial batch release.